Sugi Predict

Sugi Predict / Compounds / SCHEMBL47040

SCHEMBL47040

SCHEMBL47040

O=c1c2ccc(Br)cc2oc2ccc(Br)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ GFER P55789 1/20 0.50
▸ CYP11B1 P15538 1/20 0.49
▸ CYP11B2 P19099 1/20 0.49
▸ KMT2A Q03164 2/20 0.48
▸ PTPN1 P18031 1/20 0.47
▸ MAOA P21397 3/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ PGAM1 P18669 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30593469 1.00 PIM1 (0.51) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL17752292 0.92 CYP11B1 (0.54) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL30923496 0.92 CYP11B1 (0.54) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL29416622 0.92 PIM1 (0.58) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL2588529 0.92 PIM1 (0.58) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL21468257 0.88 TTR (0.58) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL10170969 0.88 CYP11B1 (0.44) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL21327540 0.88 MAOA (0.66) PIM1SMN1; SMN2MAPTKMT2AMAOA
SCHEMBL1992744 0.88 CSNK2A2 (0.55) PIM1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL2628177 0.88 CSNK2A2 (0.58) SMN1; SMN2MAPTNPC1RAB9AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290438-A Diamine precursor, polyimide and transparent polyimide film based on spiro-bisxanthene structure and manufacturing method thereof 大连理工大学 2024-07-05 — — CN disclosed
CN-111484468-B Compound for preparing organic photoelectric device 烟台显华光电材料研究院有限公司 2023-09-22 — — CN disclosed
CN-111484468-A Compound for preparing organic photoelectric device 烟台显华光电材料研究院有限公司 2020-08-04 — — CN disclosed
CN-111269419-A Polyimide applicable to FOLED substrate and preparation method thereof 湖南工业大学 2020-06-12 — — CN disclosed
CN-111116538-A Diamine with antibacterial effect and preparation method thereof 湖南工业大学 2020-05-08 — — CN disclosed
CN-111072975-A Polyimide for FOLED substrate and preparation method thereof 湖南工业大学 2020-04-28 — — CN disclosed
US-20180170894-A1 LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2018-06-21 — — US disclosed
US-20180170894-A1 LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2018-06-21 — — US disclosed
US-9929354-B2 9,9′-spirobixanthene derivatives for electroluminescent devices MERCK PATENT GMBH (DE) 2018-03-27 — — US disclosed
US-9929354-B2 9,9′-spirobixanthene derivatives for electroluminescent devices MERCK PATENT GMBH (DE) 2018-03-27 — — US disclosed
EP-2580209-A2 INHIBITORS OF HCV NS5A PROTEIN Presidio Pharmaceuticals, Inc. (US) 2013-04-17 — — EP disclosed
WO-2012050918-A2 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICAL, INC. (US) 2012-04-19 — — WO disclosed
WO-2012050918-A2 TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICAL, INC. (US) 2012-04-19 — — WO disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
WO-2012003642-A1 FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2012-01-12 — — WO disclosed
WO-2011156543-A2 INHIBITORS OF HCV NS5A PROTEIN PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-15 — — WO disclosed
WO-2011156543-A2 INHIBITORS OF HCV NS5A PROTEIN PRESIDIO PHARMACEUTICALS, INC. (US) 2011-12-15 — — WO disclosed
WO-2010111534-A1 FUSED RING INHIBITORS OF HEPATITIS C PRESIDIO PHARMACEUTICALS, INC. (US) 2010-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170894-A1 LIGHT EMITTING MATERIAL, MANUFACTURE METHOD THEREOF AND ORGANIC LIGHT EMITTING DIODE USING THE LIGHT EMITTING MATERIAL UBE2M, UFM1, UFL1 PIM1 2069/4885SMN1; SMN2 2946/4885MAPT 528/4885
US-20120040962-A1 FUSED RING INHIBITORS OF HEPATITIS C HAVCR2, HCCS, ZC3HAV1 PIM1 2900/4885SMN1; SMN2 4787/4885MAPT 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.